ResMed Inc. engages in the digital health and cloud-connected medical devices business in the United States and internationally. It operates in two segments, Sleep and Breathing Health, and Residential Care Software. The company offers sleep recorders for the diagnosis and titration of sleep apnea in sleep clinics, hospitals, and at home, including ApneaLink Air, a portable diagnostic device that measures oximetry, respiratory effort, pulse, nasal flow, and snoring; NightOwl, a portable, cloud-connected, and disposable diagnostic device that measures AHI based on derived peripheral arterial tone, actigraphy, and oximetry; and EasyCare Tx, a sleep lab solution. It also provides AirView, a cloud-based system that enables remote monitoring and changing of patients' device settings; myAir, a personalized therapy management application for patients with sleep apnea that provides support, education, and troubleshooting tools for increased patient engagement and improved compliance; and connectivity module which provides a cellular connection between compatible ventilation devices and AirView system. In addition, the company offers Brightree solutions which are solutions and services for organizations in home medical equipment and pharmacy, orthotic and prosthetic, and home infusion; HEALTHCAREfirst solutions that offers electronic health record, software, billing and coding services, and advanced analytics that enables home health and hospice agencies to optimize clinical, financial and administrative processes; MatrixCare EHR software as a service solutions used by skilled nursing and senior living providers, life plan communities, and home health and hospice sectors; and MEDIFOX DAN software solutions that is used by residential care providers, such as home health and nursing home providers. ResMed Inc. was founded in 1989 and is headquartered in San Diego, California.
Price analytics
Returns
1 day
0.8%
1 week
0.7%
1 month
-0.9%
3 months
1.1%
6 months
-3.7%
1 year
-24.5%
3 years
38.3%
Risk
Volatility (1y ann.)
29.4%
Beta vs ASX 200
0.39
Sharpe (1y)
-0.94
VaR 95% (1-day)
-3.1%
Max drawdown (1y)
-39.9%
Off 1-year high
-26.1%
Technicals
RSI(14)
69
vs 50DMA
1.4%
vs 200DMA
-0.9%
Trend
Death cross
Fundamental trends
Financial statements
Loading…
Scoring breakdown
(2 Oct 2026)
Value63.4
Trailing P/E
58
Forward P/E
68
PEG ratio
69
EV / EBITDA
73
Price / Book
84
Price / Sales
20
Growth64.4
Revenue growth (1y)
57
Revenue CAGR (3y)
61
EPS growth (1y)
59
EPS CAGR (3y)
85
Financial Health100.0
Net debt / EBITDA
100
Interest coverage (EBIT/interest)
—
Current ratio
100
Debt / Equity
100
Quality (Profitability & Cash Flow)99.6
Return on equity
100
Return on assets
100
Operating margin
100
Net margin
100
Cash conversion (OCF / net income)
98
Dividend / Income71.4
Dividend yield (%)
20
Payout ratio
100
FCF dividend cover
100
Momentum45.0
6-month return vs ASX 200
42
Price vs 200-day average
47
Price vs 50-day average
57
Position in 52-week range
35
Hover a row's info icon for the exact rule. Bounds and weights are configurable in
the Django admin (Scoring configuration).